Surgery Partners, Inc. has announced an increase in the consent fee for its bondholders as part of a consent solicitation related to a merger. The company revealed this update in a filing with the SEC on November 18, 2026. This move is significant as it aims to facilitate their merger with Spyglass Topco, LLC, which could reshape the competitive landscape in the healthcare industry.
According to the filing, Surgery Center Holdings, Inc., a wholly owned subsidiary of Surgery Partners, is conducting a consent solicitation from holders of its outstanding $1.225 billion aggregate principal amount of 7.250% Senior Notes due 2032. The consent fee for those who validly deliver consents before the expiration has been raised from $2.50 to $5.00 per $1,000 in principal amount of Notes. The solicitation will expire at 5:00 p.m. New York City time, on November 20, 2026, unless extended or earlier terminated.
The increase in the consent fee is aimed at securing the necessary approvals for amendments to the indenture governing the Notes. These amendments are crucial for the upcoming merger, as they will allow certain affiliates of Bon Secours Mercy Health, Inc. to be classified as "Permitted Holders" under the indenture. This classification is essential for the merger's completion, as it would otherwise trigger a "Change of Control" under the existing terms.
Founded in 2016, Surgery Partners, Inc. operates within the SIC category of Services-General Medical & Surgical Hospitals, NEC. The company is listed on the Nasdaq under the ticker symbol SGRY. The proposed merger with Spyglass Topco, LLC, which was initially announced on October 23, 2026, is part of Surgery Partners' strategy to enhance its market position and expand its service offerings.
The consent solicitation is related to Surgery Partners' entry into an Agreement and Plan of Merger with Spyglass Topco, LLC, and its subsidiary. The merger is expected to provide Surgery Partners with additional resources and capabilities, potentially benefiting its operational efficiencies and service delivery.
The filing indicates that the consent solicitation is being conducted in accordance with the terms set forth in the Consent Solicitation Statement dated November 16, 2026. This document outlines the conditions and details of the proposed amendments, emphasizing the importance of the bondholders' consent for the merger's success.
Stakeholders in the healthcare sector, including investors, employees, and patients, may be affected by the outcomes of this merger and the changes in the consent solicitation process. The adjustments in the consent fee may encourage bondholders to participate, thereby increasing the likelihood of a successful amendment to the indenture.
Looking ahead, the company is expected to continue its efforts to secure the necessary consents from bondholders. The filing does not specify what happens next, but the upcoming expiration of the consent solicitation will be a critical milestone for Surgery Partners as it navigates this significant merger.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





